Sign in
Taking peopleNo phase

Long Passeo-18 Lux drug-coated balloon for blocked leg arteries

Tests a long drug-coated balloon in peripheral arterial disease.

Key facts

Who runs it
KANDO Research
Where
Belgium4 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions
Status
Recruiting
People taking part
200 people, planned
Started
1 Jul 2026
Expected to end
Jan 2032
Type of study
Interventional
Treatments tested
  • Percutaneous Transluminal Angioplasty with the use of Passeo-18 Lux DCB
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narrowed or blocked leg arteries (peripheral arterial disease). They will be treated with the Passeo-18 Lux drug-coated balloon.

Age
18 to 99 years
Sex
All sexes
Disease stage
New narrowing, narrowing that came back after plain balloon treatment, or a full blockage in the leg arteries above or below the knee. The narrowing must be at least 70%, at least 3cm (1.2 in) long, in a vessel 2-7mm wide. Rutherford Class 2-5.
Earlier treatment
People who had bypass surgery on the target vessel cannot join.
Biomarker or test result
Imaging of the artery (angiography) must show ≥70% narrowing. After first widening with a balloon, less than 50% narrowing may remain.

Main reasons for not taking part

  • Expected to live 1 year or less
  • Pregnant, planning pregnancy, or planning to father a child during the study
  • Planned major amputation of the treated leg
  • Blood clot in the treated vessel
  • One lesion reaching both above and below the knee

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Study participant is ≥ 18 years and ≤ 99 years old
  • Lesion(s) in the infrainguinal arteries:; Lesion above the knee (ATK): Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau); Lesion below the knee (BTK): Target lesions involve arteries below the tibial plateau
  • RVD 2-7mm
  • De novo stenotic, restenotic post POBA, or occlusive lesion(s)
  • Target lesion must have angiographic evidence of ≥70% stenosis
  • Lesion length ≥ 3cm
  • Successful crossing of the target lesion with the guide wire
  • Successful predilatation, defined as residual stenosis <50% Rutherford Class 2-5
  • Study participant is able to provide consent and has signed and dated the informed consent form

Who cannot take part

  • Study participant is currently participating in another investigational drug or device study that has not reached its primary endpoint yet
  • Prior bypass surgery of target vessel
  • Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion)
  • Known allergy to contrast media that cannot be adequately controlled with premedication
  • Life expectancy ≤ 1 year
  • Study participant is pregnant, planning to become pregnant, or father children during the course of the study
  • Planned major amputation of the target limb
  • Thrombus in the target vessel
  • Study participant has a single target lesion that involves both ATK and BTK segments

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial will evaluate the study device, Passeo®-18 Lux® paclitaxel-releasing percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of new or recurring cholesterol-related blockages in the arteries of the lower leg.

Read full original descriptionShow less

The device that is used in this trial has been assessed in several previous studies for safety and effectiveness. The device is already approved for use in Europe. It has a "CE mark," which means it meets the European Union's safety, health and performance standards.

This trial is being done to gather additional information on how well the device works and how safe it is when used in everyday medical care with specific attention to the longer lengths of the balloon, as it comes in different sizes.

The group in the trial

  • Passeo-18 Lux ArmTreatment being tested

    All trial participants will be treated with the same Passeo-18 Lux drug coated balloon (which comes in different sizes).

    Treatment: Percutaneous Transluminal Angioplasty with the use of Passeo-18 Lux DCB

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions
Plain-language title
Long Passeo-18 Lux drug-coated balloon for blocked leg arteriesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07385573, who can take part
Record updated
10 September 2026